HSD17B12: A Potential Drug Target for Androsteroid Synthesis and Regulation

Target Name: HSD17B12

NCBI ID: G51144

HSD17B12

HSD17B12: A Potential Drug Target for Androsteroid Synthesis and Regulation

HSD17B12, also known as steroid dehydrogenase homolog, is a gene that encodes a protein involved in the synthesis of androsteroids, which are a class of hormones that play a critical role in various physiological processes in the body. HSD17B12 is a key enzyme in the 17-beta-hydroxysteroid dehydrogenase (17-beta-HSD) gene family, which is responsible for the production of androsteroids from androgens, such as androstenedione and androsterone.

HSD17B12 is a member of the superfamily of cytoskeletal proteins known as the coiled-coil domain containing proteins (CCD-P), which are characterized by the presence of a coiled-coil domain that plays a structural role in the protein's stability and functions. The CCD-P family is a subset of the large protein family known as the HSP70/40 family, which is known for their ability to form covalent bonds with a variety of molecules, including small molecules, ions, and other proteins.

HSD17B12 is expressed in various tissues throughout the body, including the brain, heart, kidneys, and reproductive organs, and is involved in the production of androsteroids, which are essential for various physiological processes, including sexual function, bone growth and maintenance, and stress response. In addition to its role in androsteroid synthesis, HSD17B12 is also involved in the regulation of cell proliferation and apoptosis, as well as in the development and progression of various diseases, including cancer.

Due to its involvement in androsteroid synthesis and regulation, HSD17B12 has been identified as a potential drug target for the treatment of various diseases. One of the main goals of drug development is to identify compounds that can modulate the activity of a protein and enhance its function, either by interacting with it directly or by inhibiting its activity. This is the case with HSD17B12, as researchers are interested in developing drugs that can either activate or inhibit the activity of this protein.

One of the key challenges in targeting HSD17B12 as a drug candidate is its complex structure and the fact that it is expressed in various tissues throughout the body. In order to develop effective treatments, it is important to have a clear understanding of the underlying biology of HSD17B12 and how it functions in the body. This is an area in which research is still in its infancy, and much more research is needed to fully understand the role of HSD17B12 in various biological processes and to develop effective treatments.

In conclusion, HSD17B12 is a protein involved in the synthesis of androsteroids and is expressed in various tissues throughout the body. Its structure and function make it an attractive target for drug development, with potential treatments for various diseases. Further research is needed to fully understand the role of HSD17B12 in various biological processes and to develop effective treatments.

Protein Name: Hydroxysteroid 17-beta Dehydrogenase 12

Functions: Catalyzes the second of the four reactions of the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of two carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. This enzyme has a 3-ketoacyl-CoA reductase activity, reducing 3-ketoacyl-CoA to 3-hydroxyacyl-CoA, within each cycle of fatty acid elongation. Thereby, it may participate in the production of VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. May also catalyze the transformation of estrone (E1) into estradiol (E2) and play a role in estrogen formation

The "HSD17B12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSD17B12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets